Announcements Trials
Browse Landscape

Phase

Phase 2 10Phase 1 3Phase 3 1Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1CNS 1Breast 1

Conditions

Squamous Cell Carcinoma of Head and Neck 3Carcinoma, Non-Small-Cell Lung 3Pancreatic Neoplasms 2Colorectal Neoplasms 2Stomach Neoplasms 1Rhabdomyosarcoma 1Neuroectodermal Tumors 1Neoplasms 1Neoplasm Metastasis 1NSCLC 1Lung Neoplasms 1Gastrointestinal Neoplasms 1Fanconi Anemia 1Esophageal Neoplasms 1Colonic Neoplasms 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

Trastuzumab 62Paclitaxel 57Cyclophosphamide 44pembrolizumab 34Fulvestrant 34Capecitabine 29Carboplatin 26Docetaxel 23Letrozole 22Doxorubicin 19palbociclib 16abemaciclib 16pertuzumab 15durvalumab 14Filgrastim 13Everolimus 13ribociclib 12Lapatinib 12Gemcitabine 12exemestane 11eribulin 11Vinorelbine 11Albumin-Bound Paclitaxel 11Bevacizumab 10trastuzumab deruxtecan 9neratinib 9fludarabine 9Taxes 9Radiotherapy 9Peripheral Blood Stem Cell Transplantation 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Breast Neoplasms × Afatinib × Clear all
NCT02768337 2024-01-31

CamBMT1

Cambridge University Hospitals NHS Foundation Trust

Phase 1/2 Terminated
26 enrolled
BreastCNSThoracic

Brain Neoplasms, Breast Neoplasms, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡